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Abstract
Background: Comprising of both organisational and patient level components, collaborative care
is a potentially powerful intervention for improving depression treatment in UK primary Care.
However, as previous models have been developed and evaluated in the United States, it is
necessary to establish the effect of collaborative care in the UK in order to determine whether this
innovative treatment model can replicate benefits for patients outside the US. This Phase III trial
was preceded by a Phase II patient level RCT, following the MRC Complex Intervention
Framework.
Methods/Design: A multi-centre controlled trial with cluster-randomised allocation of GP
practices. GP practices will be randomised to usual care control or to "collaborative care" - a
combination of case manager coordinated support and brief psychological treatment, enhanced
specialist and GP communication. The primary outcome will be symptoms of depression as
assessed by the PHQ-9.
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Discussion: If collaborative care is demonstrated to be effective we will have evidence to enable
the NHS to substantially improve the organisation of depressed patients in primary care, and to
assist primary care providers to deliver a model of enhanced depression care which is both
effective and acceptable to patients.
Trial Registration Number: ISRCTN32829227
Background
Depression is a major health problem causing substantial
disability and set to become the second largest cause of
global disability by 2020 [1,2]. Despite the availability of
effective pharmacological and psychological treatments
for depression, patients often receive a less than optimal
treatment programme. In primary healthcare systems
internationally, patient adherence with pharmacological
treatment is poor [3] and problems are exacerbated fur-
ther by organisational barriers between generalist and spe-
cialist mental health professionals [4,5]. Generalist
primary care physicians often have very limited support
when helping patients with both pharmacological treat-
ment and psychosocial interventions. Such support may
be critical given that in systems such as that in the United
Kingdom (UK) and elsewhere, the general practitioner
(GP) is the sole responsible medical clinician for 90-95%
of patients [6].
Attempts to improve this situation have seen the develop-
ment of organisational strategies including increased
resources to specialist services, education of primary care
clinicians, consultation liaison services and stepped care
[7]. A systematic review of 36 organisational intervention
studies concluded that simple models such as guidelines
and education were ineffective in improving the manage-
ment of depression [8]. Gunn et al [9] identified the com-
ponents of effective organisational quality improvement
strategies as: a multi-professional approach to patient
care; a structured management plan; scheduled patient
follow-ups; and enhanced inter-professional communica-
tion.
One model which has seen an increasing efficacy and
effectiveness literature is 'collaborative care' [7] which
highlights the chronic nature of depression and proposes
that the whole system of care for depression needs to be
reengineered. Collaborative care is a complex combina-
tion of clinician and patient education, consultation-liai-
son between primary and secondary care clinicians and
case management [10], translated into practice by the
introduction of a new case manager role into primary care
who liaises between primary care clinicians and mental
health specialists, collects and shares information on the
clinical care of individual patients and delivers and man-
ages aspects of their care [7].
Whilst collaborative care improves outcomes over usual
care [11-13], the vast majority of models have been devel-
oped and evaluated in the United States (US) [14]. Given
this, it is necessary to establish the international generalis-
ability of collaborative care to determine if these out-
comes can be replicated beyond the US, where the nature
of patient populations and patterns of service utilization
may differ. The feasibility and acceptability of implemen-
tation in the UK National Health Service (NHS) is likely
to be shaped by funding arrangements, deployment of
staff and the structure and organization of component
parts of the NHS (particularly primary care).
In order to investigate collaborative care in the UK, we
adopted the UK Medical Research Council's (MRC)
[15,16] strategy for the investigation of complex interven-
tions. Through a series of exploratory qualitative and
quantitative studies as part of a 'Trial Platform' funded by
the Medical Research Council [17-20] we found collabo-
rative care to have a moderate to large effect (0.63; 95%
confidence interval = 0.18 to 1.07), the first time this has
been demonstrated in the UK, with change in PHQ-9
scores achieved by the intervention patients from baseline
to follow up equating to a clinical shift of almost two cat-
egories of depression severity. We also found that the best
method of recruitment was through case finding and that
collaborative care was acceptable to patients and mental
health workers. As a consequence, we have designed a
fully powered trial of collaborative care as the next step in
our phased approach to investigating this complex inter-
vention.
Methods/Design
Objectives
Is collaborative care more clinically and cost effective than
usual care in the management of patients with moderate
to severe depression in UK primary care?
Study Design
This is a pragmatic cluster randomised controlled trial
with allocation of clusters (GP practices) to two alterna-
tive branches (see Figure 1)
1) Collaborative care (experimental group)
2) Usual management of depression (control group)
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Consort diagram detailing progression through the trialFigure 1
Consort diagram detailing progression through the trial.
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The rationale for a cluster randomised trial comes from
data collected in our trial platform [19] where we tested
directly for the presence of contamination between exper-
imental and control conditions. In this pilot phase, after
initially randomising General Practices to treatment or
cluster control conditions, patients in the treatment clus-
ter group were then individually randomised to either col-
laborative care or usual care control. This created three
study groups (cluster-randomized controls, individually-
randomized intervention patients, individually-rand-
omized control patients). Our results showed evidence for
substantial contamination, in that when compared to the
intervention group's outcomes, patients in the patient-
randomised control group (who received no direct
patient-level interventions, but may have benefited from
organisational effects at the cluster level) had better out-
comes (coefficient = -2.99 95% CI -7.56 to 1.58, p =
0.186) than those in the cluster-randomised control who
received neither patient- nor organisational-level inter-
vention (coefficient = -4.64; 95% CI -7.93 to -1.35, p =
0.008). The intra-class correlation co-efficient (ICC) for
our primary outcome was 0.06 (95% CI = 0.00 to 0.32).
This suggests that the effect of the intervention was partly
mediated through organisational effects. Therefore, we
had to conclude that a patient-randomised trial of collab-
orative care could be vulnerable to contamination and
open to type II error - underestimating the true effect size
of the intervention through potential intervention 'leak-
age'. As a consequence, a cluster-randomised controlled
trial design is the safest in order to minimise this potential
source of bias and provide a truer estimate of the collabo-
rative care intervention effect size.
Recruitment of GP practices
We will recruit 48 GP practices in three different recruit-
ment sites: Manchester, London and Bristol, each site
responsible for the recruitment of 16 practices. All GP
practices in the local Primary Care Trust (PCT) will be eli-
gible for inclusion.
Randomisation of GP Practices
We will allocate practices by minimisation, with a random
element, on centre, deprivation and practice size. We will
use the Index of Multiple Deprivation 2007 [21] to assess
the level of deprivation in each practice.
Patient Recruitment
Sample Size
We have powered this trial to detect an effect size of 0.4.
Our effect size is towards the conservative end of our plat-
form trial confidence interval [19] SMD: 0.63; 95% CI
0.18 to 1.07, an effect size achieved by Pilling et al [22]
SMD 0.42; 95% CI -0.05 to +0.89, and in line with the
findings of recent reviews [23] and our group's recent
meta regression [14]. An effect size of 0.4 is also regarded
as the most reasonable for determining differences
between interventions that are clinically meaningful [24].
Such an effect size at 90% power (alpha 0.05) would
require 132 patients per group in a two armed patient ran-
domised trial. For the proposed cluster trial, with 14
patients per cluster and the ICC found in our trial plat-
form of 0.06, the design effect would be 1.65. The cluster
trial sample size is, therefore, 440. In order to follow up
440 patients, we will recruit and randomise 550 patients
to anticipate a loss to follow up of 20%.
Patient inclusion criteria
We will include patients meeting the diagnostic criteria for
depression who are aged 18 years and above and who are
not currently receiving treatment for depression from spe-
cialist mental health services. We will establish the diag-
nosis of depression by the use of the Clinical Interview
Schedule (CIS-R) [25] undertaken by a research worker.
We will include both patients newly identified as
depressed, with or without one or more previous depres-
sive episodes, and those with an existing diagnosis of
depression which is not responding to primary care man-
agement. We will also include patients who are suffering
from peri- or post-natal depression, with either co-morbid
physical illness or co-morbid non-psychotic functional
disorders, such as anxiety. In line with the pragmatic
nature of this trial, we will reflect usual GP care and par-
ticipants will be eligible to participate whether they are in
receipt of antidepressant medication or not.
Patient Exclusion Criteria
We will exclude patients whose risk of suicide is suffi-
ciently acute to demand immediate management by a spe-
cialist mental health crisis team. We will exclude patients
with psychosis, both type I and type II bi-polar disorder,
patients where the low mood is better explained by the
death of someone close to them and patients whose pri-
mary presenting problem is alcohol or drug abuse.
Patients who are currently receiving specialist treatment
for their depression will also be excluded.
Patient Identification and Recruitment
Cluster trials are vulnerable to selection bias through sys-
tematic differences in referral behaviour between experi-
mental and control practices. We will minimise this
potential bias by recruiting patients through searching GP
records, rather than by direct GP referral. This method was
also the most productive when we tested a range of
recruitment methods in our pilot trial [17]. We will iden-
tify suitable patients by examining electronic case records
for all patients in each general practice. The search will be
limited to patients seen by their GPs in the previous four
weeks who have been allocated a 'Read Code' for depres-
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sion, and will be conducted by practice staff or Clinical
Studies Officers blind to the random allocation of the GP
surgery.
Identified patients will receive a letter from their GP sur-
gery inviting them to take part in the study, enclosing a
patient summary sheet outlining the study with a 'Permis-
sion for researcher to contact' form to allow a researcher
to contact them. Recruitment which requires patients to
return paper forms is known to have a very poor response
rate, typically only 15% of those contacted will agree to be
contacted, a threat to the study's external validity. A recent
review of RCT recruitment methods [26] showed that the
only likely method of improving recruitment was through
telephone reminders by clinicians to non-responders.
Consequently, in order to make our sample more repre-
sentative of a primary care depressed population, we will
attempt to enhance our response rate through telephone
follow up by practice staff or Clinical Studies Officers.
Screening and Baseline
At the screening appointment the researcher will confirm
the diagnosis of depression using the CIS-R [25]. The CIS-
R is a computerised interview schedule that establishes the
nature and severity of neurotic symptoms and identifies a
categorical diagnosis of mild, moderate or severe depres-
sion. If the patient is depressed and meets all other inclu-
sion criteria we will collect baseline primary and
secondary outcome measures.
Allocation
Once the baseline assessments are complete, the partici-
pant's details will be entered into our automated alloca-
tion service via telephone or the internet. Each participant
will be assigned an ID number and if their practice is one
assigned to collaborative care then the participant's details
will be automatically sent to the relevant case manager to
alert them to contact this person. All new participants'
details are also sent to the trial coordinator and their GP
will be informed of their involvement in the study.
Intervention - Case Management
The experimental intervention will follow the criteria
identified by Gunn et al [9] for effective quality improve-
ment strategies, which we have developed into a collabo-
rative care protocol, tailored to UK systems and
incorporating the preferences of patients, specialists and
GPs from our trial platform [17,20].
Participants will receive a structured management plan
including education about depression, medication man-
agement, behavioural activation and relapse prevention.
The case manager will reinforce the information given to
participants by their GP and by helping participants and
GPs problem solve any difficulties with medication con-
cordance, enabling participants to make good use of their
medicines. Behavioural Activation (BA) is an effective cog-
nitive-behavioural treatment of depression [27] that
focuses upon reducing avoidance and increasing activity.
We found BA to be acceptable in our pilot trial [20].
Relapse prevention will involve the development of indi-
vidualised recovery plans which will help participants
identify signature alert symptoms to prompt them to con-
sider reinstating both their pharmacological and psycho-
logical depression management strategies.
Scheduled patient follow-ups will be organised via six to
twelve scheduled telephone and face-to-face contacts by
case managers with participants over a period of fourteen
weeks. After an initial face-to-face contact most other con-
tacts will be by telephone, although the option for further
face-to-face contacts will be available for participants who
are having difficulty settling to telephone contact. Negoti-
ation of contact frequency will take into account partici-
pant preference, response to treatment, the requirements
of the psychosocial support programme and the amount
of GP-patient contact. However, in general, contacts will
be weekly for the first five weeks of contact, followed by
fortnightly thereafter. The initial contact session will be
30-40 minutes with subsequent sessions 15-20 minutes
each.
Case manager training and supervision
Case Managers will be either graduate psychologists or
health care qualified professionals educated through
existing mental health education programmes and trained
specifically to deliver the collaborative care protocol. Case
managers will adhere to a clinical protocol and will be
supported by specialist mental health professionals who
will provide weekly supervision of cases together with
advice and support. Supervision for each individual par-
ticipant will be no less than four weekly and will be facil-
itated through a bespoke computerised patient
management system (PC-MIS) [28] which automatically
alerts supervisors of the need to discuss all new patients,
each participant at four weekly review and those partici-
pants who are not responding to treatment.
Control intervention - Usual GP Care
Participants allocated to the control condition will receive
usual care by their general practitioner. In line with the
overall pragmatic approach of the trial, we will replicate
'normal GP practice' by making no specific patient-level
recommendation or requirement to alter usual care by
participating in the trial. GPs will treat and refer partici-
pants as would be their normal practice and participants,
irrespective of their randomisation, are able to choose
whether or not to take anti-depressants or ask for referral
for psychological therapy. We will record every aspect of
participant's usual care.
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Outcome Parameters
Primary outcome measure
Our primary outcome will be depression severity and
symptomatology as measured by the Patient Health Ques-
tionnaire-9 (PHQ9) [29] at four months. The PHQ9 is a
nine-item questionnaire, which records the core symp-
toms of depression.
Secondary outcome measures
We will measure quality of life using the SF36 [30], worry
and anxiety by the GAD7 [31], health care utilisation
using a bespoke designed patient service utilisation ques-
tionnaire, health state utilities with the EQ5D [32] and
patient satisfaction with the CSQ8 [33,34]. All measures
will be taken at baseline, four and twelve months follow
up (see table 1), except the CSQ-8 which will only be
taken at four months. In all cases, steps will be taken to
ensure that the researcher who is assessing depressive
symptomatology is blind to the participant's treatment
arm of the trial.
Process Data
Process data will be collected within the trial. The exten-
sive quantitative and qualitative work in our pilot trial has
indicated that the planned intervention is effective and
acceptable, and our process evaluation in this main trial
will focus on (i) mechanisms of change and differential
response in patient subgroups, and (ii) the process of
implementation of the intervention [35]. Investigation of
mechanisms of change and differential response in partic-
ipant subgroups will include quantitative measurement of
key participant's baseline characteristics (e.g. severity of
depression; duration of depression; patient preferences;
attitudes towards treatment), treatment process measures
(e.g. therapeutic alliance; concordance with treatment;
behavioural activity levels), contextual practice variables
(e.g. anti-depressant prescription rates; availability of
counselling and other mental health services) and will fol-
low conventional procedures for analysis [36]. Investiga-
tion of the process of implementation will utilise
routinely collected data from case records, session audio
tapes and supervision records. The analysis will examine
the implementation of collaborative care, treatment fidel-
ity, differences between sites and different case managers
and predictors of outcome.
Analysis
Statistical analysis of clinical data
We will analyse our primary outcome of severity of
depression on the PHQ-9 at four months using between
groups analysis of covariance on individual baseline
depression score. Analysis will take clustering into
account by use of robust standard errors in Stata. All other
clinical outcome variables will be analysed as secondary
variables in the same way, using least squares or ordered
logistic regression as appropriate. We will analyse out-
comes by site variables to detect any effects on treatment
outcomes of a 'therapist effect' - differences between case
managers - and practice level variables. We will investigate
the effects of any missing data using imputation by best
subset regression and apply CONSORT standards for clus-
ter randomised trials [37] in data reporting.
The incremental cost per QALY of the intervention com-
pared to the control will be calculated from NHS and Per-
sonal Social Services (PSS) perspectives following NICE
evaluation guidance [38] and a wider societal perspective.
The units of resource for the intervention will be collected
directly and the use of other health care services by both
groups will be collected through a patient questionnaire.
Data on social care, other welfare services and employ-
ment details will be collected from the Patient Service Uti-
lisation questionnaire. Intervention costs will be based on
delivery costs within the trial and include supervision and
appropriate capital and overhead amounts. Other unit
costs will be based on long run opportunity costs and
drawn from national sources. Full sensitivity analyses will
be conducted with bootstrapping to provide confidence
intervals around cost and effect estimates and to produce
cost acceptability curves.
Qualitative data will be subject to content analysis within
a qualitative methodological framework using QSR NVivo
software and analysed according to the conceptual matrix
of Miles and Huberman [39].
Frequency of analyses
We will analyse data at four and twelve months follow up.
The DMEC will undertake an interim data analysis to
detect any reason for halting the trial.
Ethical Issues
We will conduct the trial is such a way as to protect the
human rights and dignity of the participants as reflected
in Helsinki Declaration [40]. Participants will not receive
any financial inducement to participate. The study has
received Multi-Centre Research Ethics Committee
Table 1: Outcomes and Instrument
Outcome Parameter Instrument
Primary Outcome
Depression PHQ-9
Secondary Outcome
Quality of Life SF36
Worry and Anxiety GAD7
Health Care Utilisation Patient Service Utilisation questionnaire
Health State Utilities EQ5D
Satisfaction with Care CSQ-8
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approval from the South West Research Ethics Committee
in the UK. Local Research Ethics Committee and NHS
Research and Development approvals have also been
given for each recruitment site. To conform to data protec-
tion and freedom of information Acts, all data will be
stored securely and anonymised wherever possible. No
published material will contain patient identifiable infor-
mation.
Obtaining informed consent from participants
Informed consent will be determined by a two phase con-
sent process. Participants will receive a study information
sheet in the post and a form seeking their permission to
be contacted by a member of the research team, not at this
stage to give consent to trial participation. Full informed
consent will only be obtained through an interview by a
researcher where the information sheet is fully explained
and where the opportunity to ask questions is given. The
opportunity to withdraw from the trial will be fully
explained. Researchers seeking consent will be fully
trained and supervised by the CI and site leads. Commu-
nication and recording systems will be set up to enable the
trial team to monitor and act on participants' wishes to
withdraw from the trial.
Risks and anticipated benefits for trial 
participants and society
All participants will receive usual GP care, and therefore
no treatment will be withheld to participants in this trial.
This trial may in fact benefit individual participants, since
collaborative care is not routinely available and has been
shown to be effective in our trial platform. By participat-
ing in this trial, participants will also receive a more inten-
sive level of monitoring than that normally received in
primary care.
Informing potential participants of possible 
benefits and known risks
The patient information leaflets will provide potential
participants with information about the possible benefits
and any known risks of taking part in the trial. Partici-
pants will be given the opportunity to discuss this issue
with either their GP or trial coordinator prior to consent-
ing to participate. The trial coordinator will inform the
participants if new information comes to light that may
affect the participants' willingness to participate in the
trial.
Suicide
Inherent in the nature of the condition under scrutiny
(depression) is the risk of suicide and deliberate self-
harm. All participants will be subject to usual GP care, and
the primary care physician will be responsible for the day
to day management of depression - and will ultimately be
responsible for all patient-level treatment/management
decisions - including prescribing, referral and assessment
of risk. The pragmatic nature of this trial means that we
will not seek to influence this arrangement. However, we
will follow good clinical practice in monitoring for suicide
risk during all researcher encounters with trial partici-
pants. Where any risk to participants due to expressed
thoughts of self-harm is encountered, case managers will
apply the procedures taught in the STORM training [41],
and all sites will follow a local suicide protocol. Systems
will be put into place to ensure that the CI, trial coordina-
tor and researchers will be informed should there be any
risks to the participants' safety.
Trial Steering Committee (TSC) and Data Monitoring and 
Ethics Committee (DMEC)
A Trial Steering Committee has been set up, in addition to
a data monitoring and ethics committee (DMEC). These
committees will meet at least annually. The DMEC will
undertake an interim data analysis to detect any reason for
halting the trial.
Forecast execution dates
The preparatory period started in September 2008, and
will continue for 9 months. Recruitment will begin in
June 2009 for a period of 18 months. Follow up will last
15 months, at four (T1) and 12 months (T2) after inclu-
sion (with an additional three months of back up built
in). Data analysis and reporting will take another 6
months. The entire study period will last for 48 months.
Discussion
The current trial is designed to implement evidence based
treatments within the UK primary care setting. The multi-
ple components of collaborative care for depression have
been shown to improve outcomes for patients [11-13,42].
However despite a number of collaborative care models
being currently trialled in Europe [43-45] the vast major-
ity of the evidence emerges from the US, demanding the
need to test a model that is specific to the UK context. Col-
laborative care is a complex intervention, the develop-
ment of which ideally requires a phased approach
[15,16,46]. Our trial utilises this phased approach, and
follows on from a previous Phase II trial which demon-
strated that the collaborative care intervention can be
both effective and acceptable to patients [18,20]. We have
designed this Phase III cluster trial to deal with contami-
nation issues which we explored and identified in our
Phase II trial: cluster-randomised trials are recommended
for situations where systems level interventions such as
collaborative care are to be tested [47] since patient-ran-
domised trials may be vulnerable to contamination from
the intervention to control patients.
The outcome of this trial will have implications for the
NHS, in terms of helping to improve the organisation of
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its care for depressed patients in primary care. We expect
the results to assist primary care healthcare providers to
choose how to deliver an effective model of enhanced
depression service.
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